Skip To Main Content
Michelle C. Barton on Muck Rack

Michelle C. Barton

As seen in: Nature, Cell Press, Canadian Medical Association Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Michelle C.

Contact Michelle C., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rougeole et grossesse

|
By Michelle Science, Janine Hutson, Michelle C. Barton, Département de Pédiatrie
| Canadian Medical Association Journal Verified
![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> --> <![CDATA[//><!]]> -->
Open in Who Shared View Duplicates (3) Issue with article?

Measles in pregnancy

|
By Michelle Science, Janine Hutson, Michelle C. Barton
| Canadian Medical Association Journal Verified
Measles in pregnancy poses serious maternal and fetal risks Pregnant people with measles are at higher risk of pneumonia, hepatitis, and hospitalization and have a 10-fold higher risk of death than those who are not pregnant.1 Infection also increases the risk of miscarriage, intrauterine growth restriction, and premature birth.2 Intravenous immunoglobulin (IVIG) can reduce the risk of infection or lessen the severity of measles among exposed, susceptible pregnant people One dose of IVIG (400...
Open in Who Shared Issue with article?

AMMI Canada Practice Point on the treatment of acute COVID-19 in pediatrics

|
By Julie Autmizguine, Michelle C. Barton, Catherine Burton, Devika Dixit
| jammi.utpjournals.press
SARS-CoV-2 infection is generally milder in children than in adults and most children with acute COVID-19 will uncharacteristically require any specific therapy. However, severe outcomes occur, and the burden in children should not be minimized. Pediatric COVID-19 treatment decisions should be guided by patient-level risk status (age, underlying comorbidities, and immune status), disease severity, clinical progression, and diagnostic evaluations.
Open in Who Shared Issue with article?
See all 8 articles